Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial

Kidney International

Volumn 72, Issue 7, 2007, Pages 879-885

  Bakris, G L ^a   Ruilope, L ^b   Locatelli, F ^c   Ptaszynska, A ^d   Pieske, B ^e   De Champlain, J ^d   Weber, M A ^f   Raz, I ^g  

^a UNIVERSITY OF CHICAGO   (United States)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c A MANZONI HOSPITAL   (Italy)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Hypertension; Microalbuminuria; Proteinuria; Renoprotection

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; IRBESARTAN; PLACEBO; RAMIPRIL;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXCRETION; FEMALE; GEOMETRY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIPHENYL COMPOUNDS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RAMIPRIL; TETRAZOLES; TREATMENT OUTCOME;

EID: 34648820103     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002455     Document Type: Article

References (27)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2004; 41: 47-55.
3. Hall WD. Abnormalities in kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci 1999; 317: 176-182.
4. Ruilope LM. The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2002; 13(Suppl 3): S165-S168.
5. Diercks GFH, Van Boven AJ, Hillege JL et al. The importance of microalbuminuria as a cardiovascular risk indicator, a review. Can J Cardiol 2002; 18: 525-535.
6. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
7. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004-1010.
8. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril. The HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
9. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
10. Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; e-pub ahead of print.
11. Anavekar NS, Gans DJ, Berl T et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 2004; 92: S50-S55.
12. Norris KC, Greene T, Kopple J et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006; 17: 2928-2936.
13. Chobanian A, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572.
14. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
15. Mann JF, Gerstein HC, Yi QL et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641-647.
16. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
17. Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953.
18. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
19. Atkins RC, Briganti EM, Lewis JB et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287.
20. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124.
21. Nakao N, Seno H, Kasuga H et al. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP Substudy. Am J Nephrol 2004; 24: 543-548.
22. Bakris GL, Ruilope L, Locatelli F et al. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens 2006; 20: 693-700.
23. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
24. Lea J, Greene T, Hebert L et al. Magnitude of proteinuria reduction predicts risk of end-stage renal disease: results of the AASK trial. Arch Intern Med 2005; 165: 947-953.
25. Wright Jr JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
26. Jacobs Jr DR, Murtaugh MA, Steffes M et al. Gender- and race-specific determination of albumin excretion rate using albumin-to- creatinine ratio in single, untimed urine specimens: the Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol 2002; 155: 1114-1119.
27. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 1440-1444.